The Life Sciences Report – January 2022

Wilson Sonsini is pleased to present the latest edition of The Life Sciences Report. This issue features an interview with Foresight Diagnostics co-founder and CEO Jake Chabon conducted by Matthew Meyer, the firm’s Chief Business Advisor for Life Sciences; an article on recent pharmaceutical antitrust developments and expectations for 2022; and a piece on life sciences venture financings in which firm clients participated across the second half of 2020 and the first half of 2021, as well as an article on the firm’s newly launched Salt Lake City office. In addition, the publication includes a discussion of the Genus v. FDA decision clarifying that products meeting both “drug” and “device” definitions must be regulated as devices; an article on the FDA’s regulatory framework for innovator drug products and public disclosures—and what it means for patent strategies; and a summary of select recent life sciences client highlights and upcoming events.

Please see full Newsletter below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Sonsini Goodrich & Rosati | Attorney Advertising

Written by:

Wilson Sonsini Goodrich & Rosati
Contact
more
less

Wilson Sonsini Goodrich & Rosati on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.